Transforming the Treatment of Keloid Scarring Through Precision Medicine

Keloid disease represents a significant and growing unmet need in dermatology and surgical care. The disease is characterised by abnormal scar formation that extends beyond the original wound site. Despite the availability of treatments such as surgery, corticosteroid injections, radiotherapy, and cryotherapy, outcomes remain inconsistent, and recurrence rates are persistently high.

Researchers at the University of Cape Town have developed a breakthrough therapeutic approach that shifts the treatment approach from symptom management to targeting the underlying biology of keloid formation and recurrence. The technology is built on advanced molecular profiling; it identifies key drivers of disease progression and leverages these insights to enable a more precise and effective intervention strategy.

At the core of the innovation is the novel repurposing of kinase inhibitors. These compounds are used to disrupt the signalling pathways responsible for abnormal scar formation. Preclinical data demonstrate strong, selective activity against keloid fibroblasts, as well as synergistic effects between specific drug combinations, supporting the technology’s potential to significantly reduce recurrence.

This patented platform offers a compelling commercial opportunity within the global scar management and fibrosis markets. By leveraging compounds with existing clinical safety data, it enables accelerated development timelines and reduced regulatory risk.